Dataset Information

Simultaneous control of non-coding RNA on the G2/M phase of the cell cycle in hepatocellular carcinoma [miRNA]

ABSTRACT: The differential ncRNA and mRNA expression profile was compared between hepatocellular carcinoma and paracancerous normal tissues by microarray We use microarray to detail the gene expression of hepatocellular carcinoma and paracancerous normal tissues and Identify differentially expressed genes Overall design: The tissues from hepatocellular carcinoma and paracancerous were selected RNA extraction and hybriduzation on Affymetrix miRNA arrays. We sought to Investigate the interaction of non-coding RNAs in hepatocellular carcinoma The para-cancerous tissue comes from the same patient as the tumor sample. For example, sample id Ca2 is the tumor sample, Ca2p is the the para-cancerous tissue and Ca2 and Ca2p come from the same patient 2.

INSTRUMENT(S): [miRNA-4] Affymetrix Multispecies miRNA-4 Array [ProbeSet ID version]

SUBMITTER: Guangqiang Ye

PROVIDER: GSE115016 | GEO | 2018-05-30

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	GSE115016_RAW.tar	Raw
	filelist.txt	Txt

Items per page:

1 - 2 of 2

Publications

Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma.

Shi Jun J Ye Guangqiang G Zhao Guoliang G Wang Xuedong X Ye Chunhui C Thammavong Keooudone K Xu Jing J Dong Jiahong J

PeerJ 20181016

<h4>Objective</h4>To investigate the interaction of non-coding RNAs (ncRNAs) in hepatocellular carcinoma.<h4>Methods</h4>We compared the ncRNAs and mRNAs expression profiles of hepatocellular carcinoma and adjacent tissue by microarray and RT-PCR. The relationship between different ncRNAs and mRNA was analyzed using bioinformatics tools. A regulatory model of ncRNAs in hepatocellular carcinoma cells was developed.<h4>Results</h4>A total of 1,704 differentially expressed lncRNAs, 57 miRNAs, and 2 ...[more]

PMID: 30364632

Similar Datasets

Project description:Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and the fourth leading cause of cancer mortality worldwide. It is often diagnosed at an advanced stage, and hence typically has a poor prognosis. A number of distinct molecules have been recently identified as playing a role in the control of cancer progression. However, patients with HCC have a highly variable clinical course, indicating that HCC comprises several biologically distinctive subgroups reflecting a molecular heterogeneity of the tumors. To evaluate potential biomarkers in HCC, we employed multiple methods in this study, including qPCR, immunostaining methods and tissue microarrays (TMAs), as well as histological and pathological analysis, to assess TGFβ, XPO4, elF5A2 and ANGPTL4 in cancerous and paracancerous liver tissues from 280 patients suffering from liver cancer. Our results found that all four indicators were located in the cytoplasm and distributed in cancerous and paracancerous liver tissues. Generally, there were higher levels of these indicators in paracancerous, compared with cancerous, liver tissues. These four indicators were correlated and modulated among each other. In connection with patient clinical and revisit information, statistical analysis determined that TGFβ1 in paracancerous liver tissue was positively correlated with tumor size. Higher production of TGFβ1 in paracancerous liver tissue was always associated with bigger liver tumors. XPO4 in cancerous liver tissue and TGFβ1 in paracancerous liver tissue were positively correlated with tumor differentiation. TGFβ1, ANGPTL4 and elF5A2 were also positively correlated with the T classification of tumors. Additionally, higher levels of XPO4 in cancerous liver tissue suggested that the patient would have a better prognosis and survival rate. However, higher production of XPO4 in paracancerous liver tissue suggested a worse prognosis. All the results above provide new insights into better understanding biological indicators, such as XPO4, TGFβ1, ANGPTL4 and elF5A2, in the prediction and evaluation of liver cancer, as well as signaling pathways in the control of liver cancer. XPO4 and TGFβ1 may serve as useful markers to evaluate the size and prognosis of liver cancer.